Home

Better decisions about medicines and patient care

Rahas InGen partners with biotech and pharma teams to turn human genetics and real‑world data into decision‑ready recommendations— so you can choose the right targets, prioritize indications, and design faster, more efficient clinical trials.

Start a conversation View services

Target & indication prioritizationGenetics + RWE evidence to de‑risk portfolio choices.

Biomarker discovery & patient stratificationIdentify responder subgroups and enrich trials faster.

Clinical evidence strategyDecision memos, evidence packs, and trial design guidance.

Production ML systemsDeploy models with automated testing, versioning, and drift monitoring.

Proof in practice

Results that reduce uncertainty

30–40%

Faster target‑ID decisions across prior biotech programs

0 → 1

Built genomics & data teams from scratch at AbbVie, NGM Bio, and Neuron23

30+

Peer‑reviewed publications in genetics and multi‑omics

Selected results

Recent work

Trial enrollment optimization

Built genetic risk score-based enrollment model for Phase 2 program. Improved screening efficiency and reduced enrollment timelines.

Target prioritization

Integrated multi-ancestry biobank fine-mapping for target selection. Advanced first-in-class programs into preclinical.

Companion diagnostic

Co-led NGS companion diagnostic through CLIA/CAP handoff. Set validation targets, contributed to FDA documentation.

How we work

A clear, decision‑first process

1Define the decision

Define the decision

Align on the portfolio or clinical question and the criteria that matter most.

2Assemble the evidence

Assemble the evidence

Combine genetics, multi‑omics, and real‑world data into a single evidence map.

3Deliver the recommendation

Deliver the recommendation

Get a concise, decision‑ready memo with clear next steps.